MedTrace Logo

Flaxseed Consumption, Alone and in Combination With the Mediterranean-like Diet, on Some Indicators Related to Atherosclerosis

NCT03392025 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2018-09-07

No results posted yet for this study

Summary

Flaxseed consumption has beneficial effects on cardiovascular risk factors. In addition, the benefit of the Mediterranean-like diet in primary and secondary prevention of cardiovascular diseases has been shown.The purpose of this study is to investigate the effects of flaxseed consumption, alone and in combination with the Mediterranean-like diet, in adjunct to conventional medical treatment, in improving vascular endothelial function, plasma lipid profile and high sensitivity c-reactive protein of coronary artery disease (CAD) patients.

Conditions

Interventions

OTHER

Flaxseed

Daily consumption of 30 grams flaxseed in adjunct to medical treatment for 3 months

OTHER

the Mediterranean-like diet

Weekly Mediterranean-like diet menu in adjunct to medical treatment for 3 months

DIETARY_SUPPLEMENT

Placebo

Daily consumption of one capsule of wheat fiber as placebo in adjunct to medical treatment for 3 months

Sponsors & Collaborators

  • Javad Nasrollahzadeh

    lead OTHER

Principal Investigators

  • Javad Nasrollahzadeh, Ph.D · Department of Clinical Nutrition and Diet Therapy, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences

  • Javad Nasrollahzadeh, Ph.D · Department of Clinical Nutrition and Diet Therapy, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences

  • Nafiseh Khandouzi, Ph.D student · Department of Clinical Nutrition and Diet Therapy, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2018-05-01
Completion
2018-09-01

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03392025 on ClinicalTrials.gov